



**Karolinska
Institutet**

Benefit of cervical screening above age 60 conditioning on screening history at ages 51-60

Jiangrong Wang, Bengt Andrae, Alexander Ploner, Peter Ström, Miriam Elfström,
Joakim Dillner, Pär Sparén

Karolinska Institutet, Stockholm, Sweden

2016-05-18

Background

- Swedish guideline for cervical screening
 - Every 3 years for ages 23-50
 - Every 5 years for ages 51-60

 - Previously no specific recommendation for women above 60 years of age
 - Some counties do screening up to age 65

 - Recent recommendation: make sure every woman is screened up to and including age 60

Aim

- To investigate the impact of cervical screening at ages 61-65, stratifying on screening history at ages 51-60
- Registers in use
 - Swedish National Cervical Screening Registry (NKCx)
 - National Cancer Register
 - Cause of Death Register
 - Total Population Register, Education Register, etc.


Study population

- Women born between 1919 and 1945
 - Resident in Sweden since age 51
 - Cervical screening record available since age 51
 - No cervical cancer before age 61
 - No total hysterectomy before age 61
 - Not dead or emigrated before age 61

Design – cohort

Screening attendance

Time-varying exposure (excl. diagnostic smears)



Outcome: CxCa occurrence/death


- Censoring: death, emigration, (hysterectomy,) 2011-12-31

Design – cohort

- Adeq. screened., neg.
- Inadeq. screened, neg.
- Unscreened
- Low-grade abnormalities
- High-grade abnormalities

Screening
history

Screening attendance
Time-varying exposure



Outcome: CxCa occurrence/death

- Censoring: death, emigration, (hysterectomy,) 2011-12-31

Conclusions

- Screening at ages 61-65 can largely reduce cervical cancer incidence up to age 80 for women who were not screened or had abnormalities at ages 51-60
- Among women screened with negative result(s) in their 50s, the effect of screening at ages 61-65 is not conclusive according to present evidence:
 - Tend to reduce cervical cancer incidence, but with small effect size and not significant
 - Tend to reduce cervical cancer mortality, but power is limit
 - Requires stage of cervical cancer for down-staging effect, and larger data source

Thank you for listening

Questions?